Condition: Melanoma · Breast Cancer · Renal Cell Carcinoma · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.
This description comes directly from the study's public registry record.
Licia Rivoltini · +3902/23903245 · licia.rivoltini@istitutotumori.mi.it
Paola Frati · +3902/23903036 · paola.frati@gmail.com
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05621837